Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.50 |
| ▸ | NPC1 | O15118 | 10/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467101 | 0.76 | RAB9A (0.47) | RAB9ANPC1CYP3A4CYP1A2AR | |
| Hydrochloric Acid SCHEMBL10653147 | 0.75 | RAB9A (0.65) | RAB9ANPC1CYP3A4CYP1A2AR | |
| Hydrochloric Acid SCHEMBL2415958 | 0.75 | RAB9A (0.65) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL170196 | 0.75 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL29374931 | 0.75 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL6951103 | 0.74 | CYP1A2 (0.53) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL17841789 | 0.73 | RAB9A (0.57) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL523809 | 0.73 | RAB9A (0.44) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL8102439 | 0.73 | RAB9A (0.49) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL14893149 | 0.73 | NPC1 (0.43) | RAB9ANPC1CYP3A4CYP1A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | claimed |
| US-8058305-B2 | Pyrrolidine derivatives as prostaglandin modulators | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2009-11-26 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | RAB9A 3117/4885NPC1 981/4885CYP3A4 4276/4885 |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | RAB9A 2339/4885NPC1 4515/4885CYP3A4 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.